Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0000950170-25-059555
Filing Date
2025-04-29
Accepted
2025-04-29 07:05:51
Documents
3

Document Format Files

Seq Description Document Type Size
1 DEFA14A for_filing_2025_defa14a.htm DEFA14A 50350
2 GRAPHIC img251511220_0.jpg GRAPHIC 304015
3 GRAPHIC img251511220_1.jpg GRAPHIC 197281
  Complete submission text file 0000950170-25-059555.txt   742144
Mailing Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805
Business Address 175 INNOVATION BOULEVARD WILMINGTON DE 19805 (302) 467-1280
Prelude Therapeutics Inc (Filer) CIK: 0001678660 (see all company filings)

EIN.: 811384762 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-39527 | Film No.: 25882619
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)